The U.S. Food and Drug Administration (FDA) on Wednesday approved GSK Plc’s drug as the first oral treatment for anemia caused by chronic kidney disease in adults who have been on dialysis for at least four months.
https://www.pharmalive.com/wp-content/uploads/2022/11/ReutersGSKlogo11-11-2022.webp8071200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-02-01 19:31:512023-02-02 10:48:56U.S. FDA approves GSK’s anemia drug for patients on dialysis
